Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies

Area of Science:

• Oncology
• Molecular Diagnostics
• Clinical Therapeutics

Background:

• HER2 (Human Epidermal growth factor Receptor 2) is an oncogenic driver in various cancers.
• HER2 overexpression/amplification is a targetable biomarker in 3-5% of metastatic colorectal cancers (mCRC).
• Established anti-HER2 regimens are now part of mCRC treatment guidelines.

Purpose of the Study:

• To provide a comprehensive review of HER2-targeted strategies in mCRC.
• To examine mechanisms, toxicities, and efficacy of anti-HER2 therapies.
• To discuss challenges and methodologies in HER2 testing for mCRC.

Main Methods:

• Review of established and emerging HER2-targeted strategies.
• Analysis of clinical trial data on HER2 amplification levels and genomic alterations.
• Examination of diagnostic methodologies for HER2 screening in mCRC.

Main Results:

• Quantitative HER2 assessment and comprehensive tumor profiling are vital for treatment success.
• Patient selection must consider gene-dosage, toxicity, and coexisting mutations.
• Emerging strategies include rechallenge therapies and novel agents like bispecific antibodies and antibody-drug conjugates.

Conclusions:

• Refined therapeutic strategies and precise diagnostics improve patient selection for HER2-targeted mCRC treatment.
• Novel HER2-directed therapies offer new opportunities for this patient subset.
• Accurate HER2 testing is critical for guiding treatment decisions in mCRC.